Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
J Neurol Sci
; 373: 335-338, 2017 Feb 15.
Article
en En
| MEDLINE
| ID: mdl-28131216
ABSTRACT
BACKGROUND:
Rituximab (RTX) is increasingly used in the treatment of neuromyelitis optica spectrum disorder (NMO-SD). Administration regimen is not consensual as there is no reliable biomarker of RTX efficacy. In most cases, after induction, RTX is administered systematically every 6months.OBJECTIVE:
To assess efficacy and safety of a maintenance regimen based on CD19+ CD27+ memory B-cell (mBc) detection.METHODS:
We conducted a study in two French centers, including patients with NMO-SD who received an induction therapy with RTX. We compared the number of administered infusions, relapses and EDSS depending on two maintenance schemes (S1 administration of 1g RTX infusion every 6months or S2 a scheme based on regular mBc detection. 1g RTX was administered if mBc was >0.05%)RESULTS:
40 patients were included (mean age 40.2years, F/M sex ratio 5/1). Aquaporin-4 antibodies were positive in 75% patients. Under S1 regimen, all patients received 2 infusions per year, whereas under S2, they received 1.62 infusion per year. The mean interval between infusions under S2 was 7.4months, without decrease of clinical efficacy.CONCLUSION:
In our study, mBc-based administration of RTX allowed personalizing treatment administration and in several cases to lower the cumulative dose without loss of efficacy.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Subgrupos de Linfocitos B
/
Neuromielitis Óptica
/
Medicina de Precisión
/
Rituximab
/
Factores Inmunológicos
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Neurol Sci
Año:
2017
Tipo del documento:
Article